NEW YORK, June 1, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that the Company will participate in the Stifel 2023 Virtual Cross Sector Insight Conference, which is being held June 6-7, 2023, at The Intercontinental in Boston, MA.
Rick Anderson, President of Dario, is scheduled to give a company presentation on Tuesday, June 6, 2023, at 4:45 PM EST. Interested parties can register for the presentation webcast using the link below, or schedule one-on-one meetings by contacting your Stifel representative.
Webcast Details
Date and Time: Tuesday, June 6, 2023, 4:45 – 5:15 PM
Location: Track 6 – 3rd Floor – Dartmouth/Elenor
Registration Link: https://wsw.com/webcast/stifel80/drio/2089810
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
DarioHealth Corporate Contact:
Mary Mooney
VP Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-312-593-4280
Media Contact:
Scott Stachowiak
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-646-942-5630
| Last Trade: | US$0.95 |
| Daily Change: | -0.02 -1.70 |
| Daily Volume: | 63,432 |
| Market Cap: | US$28.570M |
October 17, 2024 October 01, 2024 September 12, 2024 September 10, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
